In 2014, Fortune Magazine ran a cover story featuring Elizabeth Holmes,

a blonde woman wearing a black turtleneck staring deadpan at the camera with the headline,

this CEO's out for blood.

Elizabeth Holmes dropped out of Stanford at 19 to start a biotech company.

Today, that company, Theranos,

is worth billions and still under the radar. Holmes was the founder of Theranos, a company that

promised to revolutionize the blood testing industry. Rather than a deep vein draw, it would do all

its tests with a single drop of blood. It promised easier, cheaper,

more accessible lab tests with far better healthcare outcomes.

There's an opportunity to create a new paradigm, being able to make actionable health

information accessible to people everywhere at the time it matters most.

Holmes was persuasive and aimed her sales pitch at rich, influential people who could give her money,

and also the veneer of legitimacy.

But as it turned out, there was no revolutionary way to test blood.

This spring, she settled a lawsuit with the Securities and Exchange Commission,

though admitting no wrongdoing, and on Friday, probably the final nail went into the Theranos coffin.

Holmes was once touted as Silicon Valley sweetheart,

but today she and a former company president

had to face some serious charges.

The U.S. Attorney's Office accusing her of engaging in a multi-million dollar scheme

to defraud investors, doctors and patients.

Holmes and Ramesh Bawani both pleaded not guilty to two counts of conspiracy to commit wire fraud. If convicted, the two can each

...